PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer

Saved in:

Bibliographic Details
Main Authors:	Abul Azad, Maryam Arshad, Daniele Generali, Katharina Feldinger, Merel Gijsen, Carla Strina, Mariarosa Cappelletti, Daniele Andreis, Russell Leek, Syed Haider, Pirkko‐Liisa Kellokumpu‐Lehtinen, Ioannis Roxanis, Adrian Llewellyn Harris, Abeer Mahmoud Shaaban, Heikki Joensuu, Anthony Kong
Format:	Article
Language:	English
Published:	Wiley 2025-01-01
Series:	Cancer Communications
Online Access:	https://doi.org/10.1002/cac2.12632
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01)

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
by: Muhammad Shahid Iqbal, et al.
Published: (2014-01-01)

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
by: Andrea L. A. Wong, et al.
Published: (2012-01-01)

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
by: Nu T. Lu, et al.
Published: (2015-09-01)

Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany
by: Kirsten Merx, et al.
Published: (2016-01-01)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
by: Sara M Tolaney, et al.
Published: (2022-10-01)

Investigation of <i>ITGB3</i> Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer
by: Asiye Busra Boz Er
Published: (2024-12-01)

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
by: Anna-Maria Lazaratos, et al.
Published: (2024-12-01)

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
by: Salvatore Siena, et al.
Published: (2024-11-01)

Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
by: Salvatore Siena, et al.
Published: (2025-01-01)

A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
by: Sylvana Hidalgo, et al.
Published: (2013-01-01)

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
by: Ünal Metin Tokat, et al.
Published: (2025-01-01)

Diffuse Spontaneous Laryngeal Hemorrhage with Trastuzumab
by: Lauren Klute, et al.
Published: (2020-01-01)

Trastuzumab Resistance: Role for Notch Signaling
by: Kinnari Mehta, et al.
Published: (2009-01-01)

PTPN2 Downregulation Is Associated with Albuminuria and Vitamin D Receptor Deficiency in Type 2 Diabetes Mellitus
by: Li Zheng, et al.
Published: (2018-01-01)

Case report: JAK inhibitor treatment of immune dysregulation symptoms in a patient with PTPN2 deficiency
by: Anna Roppelt, et al.
Published: (2025-01-01)

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy
by: Huanhuan Li, et al.
Published: (2025-02-01)

Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study
by: Fei Wang, et al.
Published: (2025-01-01)

The Genetics of PTPN1 and Obesity: Insights from Mouse Models of Tissue-Specific PTP1B Deficiency
by: Ryan C. Tsou, et al.
Published: (2012-01-01)

Association of PTPN22 Haplotypes (−1123G>C/+1858C>T) with Rheumatoid Arthritis in Western Mexican Population
by: Yeniley Ruiz-Noa, et al.
Published: (2017-01-01)

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer
by: Jonathan Henricks, et al.
Published: (2025-02-01)

Arterial Stiffness in Breast Cancer Patients Treated with Anthracycline and Trastuzumab-Based Regimens
by: Özlem Yersal, et al.
Published: (2018-01-01)

‘Her Room Was Her World’: Nellie Sloggett and North Cornish Folklore
by: Simon Young
Published: (2017-12-01)

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus
by: Emad Dawoud, et al.
Published: (2025-01-01)

Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan
by: Alessandra Fabi, et al.
Published: (2025-01-01)

Her mistletoe miracle
by: FOx Roz Denny
Published: (2008)

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
by: Laura Scalambra, et al.
Published: (2025-01-01)

Tumoral Prostate Shows Different Expression Pattern of Somatostatin Receptor 2 (SSTR2) and Phosphotyrosine Phosphatase SHP-1 (PTPN6) According to Tumor Progression
by: Ariel Ernesto Cariaga-Martinez, et al.
Published: (2009-01-01)

Intrathecal Trastuzumab Treatment of the Neoplastic Meningitis due to Breast Cancer: A Case Report and Review of the Literature
by: Cristina Dumitrescu, et al.
Published: (2013-01-01)

A Cost-Effective and Robust Cell-Based Bioassay Method for Evaluating the Bioactivity of Trastuzumab-like Antibodies
by: Pooja Bharali, et al.
Published: (2024-12-01)

Prognosis and cardiotoxicity associated to adjuvant trastuzumab for breast cancer: real world study in a public health system
by: Ana Elisa Ribeiro da Silva Cabello, et al.
Published: (2025-01-01)

How Odynerus Suspends Her Egg
by: Carl G. Hartman
Published: (1944-01-01)

PROTAGORAS: HER ŞEYİN ÖLÇÜSÜ İNSAN
by: Lokman Çilingir
Published: (2022-12-01)

Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers
by: Femke A. I. Ehlers, et al.
Published: (2025-01-01)

The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status
by: Sanaa Gamrani, et al.
Published: (2023-01-01)

International Conference “Mina Loy and her Networks”
by: Elise Ottavino
Published: (2023-11-01)

Comparison between Real-Time Quantitative PCR Detection of HER2 mRNA Copy Number in Peripheral Blood and ELISA of Serum HER2 Protein for Determining HER2 Status in Breast Cancer Patients
by: Maria Savino, et al.
Published: (2009-01-01)

Catherine of Siena's wisdom on discernment and her reception of scripture
by: Diana L. Villegas
Published: (2013-06-01)

Emily Dickinson’s Line Breaks in Her Envelope Poems
by: Antoine Cazé
Published: (2021-07-01)

Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer
by: Miaomiao Jia, et al.
Published: (2024-01-01)